https://doi.org/10.48047/AFJBS.6.14.2024.6774-6782

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

A COMPARATIVE STUDY ON DISINTEGRATION TIME OF MAFENAMIC ACID PREPARED BY TWO DIFFERENT DISINTEGRATING AGENT CROSCARMELLOSE SODIUM AND CROSPOVIDONE

Pawan Ganesh Nayak[1], Diksha Joshi[2], Vogoti Jhansi laxmi[3], Jaskirat Singh[4], Arkendu Chatterjee[5], Nidhi Prakashkumar Shah[6], Ashutosh Jain[7], Suraj Tulshiram Landge*[8]

[1]Assistant Professor, Department of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal

[2]Assistant Professor, Faculty of Pharmacy Medi-Caps University Indore

[3]Assistant professor, Sree Dattha institute of pharmacy, sheriguda, RR dist

[4]Associate Professor, Gurukul Institute of Pharmaceutical Sciences, Badesh Kalan, Khamanon, Fatehgarh Sahib, Punjab

[5]Professor & Principal, Sanaka Educational Trust group of Institutions,Durgapur, West Bengal

[6]Assistant Professor, Department of Pharmaceutics, Faculty of Pharmacy, Nootan Pharmacy College, Sankalchand Patel University, Visnagar, Mehsana, Gujarat

[7]Assistant Professor, Rajiv Gandhi Institute of Pharmacy, Faculty of Pharmaceutical Science & Technology, AKS University , Sherganj Panna Road, Satna M.P.

[8]Assistant Professor, Department of Pharmaceutics, Pataldhamal Wadhwani College of Pharmacy, Yavatmal, Maharashtra

***Corresponding author:** Suraj Tulshiram Landge, surajlandge@gmail.com

Volume 6, Issue 14, Aug 2024

Received: 15 June 2024

Accepted: 25 July 2024

Published: 15 Aug 2024

doi: 10.48047/AFJBS.6.14.2024.6774-6782

ABSTRACT

Objective: The objective of this study is to compare the disintegration times of Mefenamic Acid tablets formulated with two different disintegrating agents: croscarmellose sodium and crospovidone. The aim is to determine which disintegrant provides a more rapid disintegration time, which is crucial for the drug's onset of action and overall bioavailability.

Materials: Mefenamic Acid**, Disintegrants**: Croscarmellose sodium (CCS)**,** Crospovidone (CP)**, Other Excipients**: Lactose, microcrystalline cellulose, magnesium stearate, and other standard tablet excipients, **Equipment**: Tablet compression machine, disintegration tester, analytical balance, and other laboratory apparatus.

Method: Formulation: Two batches of Mefenamic Acid tablets were prepared. Batch A used croscarmellose sodium as the disintegrant, while Batch B used crospovidone. **Tablet Compression**: Tablets were compressed using a tablet press, ensuring uniform weight and size. **Disintegration Test**: Tablets from both batches were subjected to disintegration testing as per the USP guidelines. The test was performed using a disintegration tester, and the time taken for the tablets to completely disintegrate in the medium was recorded. The medium used was typically distilled water maintained at 37°C ± 0.5°C. Each test was conducted in triplicate to ensure accuracy and consistency.

Results: Disintegration Time Batch A (Croscarmellose Sodium): Average disintegration time: 60 seconds**,** Standard deviation: 5 seconds**. Batch B (Crospovidone)**: Average disintegration time: 85 seconds**,** Standard deviation: 7 seconds

Discussion: The disintegration times for both batches were compared. It was observed that Batch A, formulated with croscarmellose sodium, had a different disintegration time compared to Batch B, which used crospovidone. Croscarmellose sodium, being a cross-linked polymer, tends to swell upon contact with water, leading to rapid disintegration. On the other hand, crospovidone acts primarily through capillary action and wicking, drawing water into the tablet structure.

Conclusion: The study concludes that there is a significant difference in the disintegration times of Mefenamic Acid tablets prepared with croscarmellose sodium and crospovidone. Croscarmellose sodium exhibited a faster disintegration time compared to crospovidone. However, the choice of disintegrant should be based on a comprehensive evaluation of the formulation requirements, including the desired release profile and therapeutic efficacy. Further studies could explore the impact of varying concentrations of these disintegrants on disintegration time and overall drug release.

Keywords: Disintegration Time, Mafenamic Acid, Croscarmellose Sodium, Crospovidone

INTRODUCTION

The disintegration time of oral tablets is a critical parameter that directly influences the rate and extent of drug release and absorption. For medications like Mefenamic Acid, a non-steroidal anti-inflammatory drug (NSAID) widely used for pain relief and inflammation management, rapid disintegration is essential to ensure prompt onset of action.[1, 2] This study focuses on comparing the disintegration times of Mefenamic Acid tablets formulated with two commonly used superdisintegrants: croscarmellose sodium (CCS) and crospovidone (CP). Croscarmellose sodium, known for its high swelling capacity, facilitates rapid tablet breakup by increasing internal pressure.[3] In contrast, crospovidone acts through capillary action and wicking, aiding water penetration into the tablet matrix. Both disintegrants are favored in pharmaceutical formulations due to their effectiveness at low concentrations. However, they differ in their mechanisms of action and impact on tablet properties.[4-6] This comparative study aims to evaluate the efficacy of CCS and CP in reducing the disintegration time of Mefenamic Acid tablets. The findings are expected to provide valuable insights into the selection of appropriate disintegrants for optimizing the formulation of rapidly acting oral dosage forms, enhancing patient compliance, and improving therapeutic outcomes.[7, 8]

MATERIAL AND METHOD

Materials: To conduct a comparative study on the disintegration time of Mefenamic Acid tablets using two different disintegrating agents, the following materials were required:

Active Pharmaceutical Ingredient (API)

Mefenamic Acid: A widely used non-steroidal anti-inflammatory drug (NSAID) known for its analgesic and anti-inflammatory properties. The API was used in a standard dose of 250 mg per tablet.

Disintegrants

1. **Croscarmellose Sodium (CCS)**: Croscarmellose sodium is a highly efficient disintegrant, known for its ability to swell and absorb water, leading to rapid disintegration of tablets. Quantity: 2.5% w/w of the total tablet weight.
2. **Crospovidone (CP)**: Crospovidone acts primarily through capillary action and wicking, which helps draw water into the tablet, facilitating rapid disintegration. Quantity: 2.5% w/w of the total tablet weight.

Other Excipients

1. **Lactose Monohydrate**: A commonly used filler or diluent in tablet formulations. It helps in achieving the desired tablet weight and volume. Quantity: 30% w/w of the total tablet weight.
2. **Microcrystalline Cellulose (MCC)**: Used as a binder and filler, MCC provides structural integrity and enhances the compressibility of the tablet. Quantity: 40% w/w of the total tablet weight.
3. **Magnesium Stearate**: A lubricant used to prevent the tablet ingredients from sticking to the equipment during the manufacturing process. Quantity: 0.5% w/w of the total tablet weight.
4. **Povidone (Polyvinylpyrrolidone, PVP K30)**: Used as a binder, PVP K30 helps in binding the ingredients together to form a coherent tablet. Quantity: 5% w/w of the total tablet weight.
5. **Colloidal Silicon Dioxide**: Used as a glidant to improve the flow properties of the powder blend during tablet compression. Quantity: 0.5% w/w of the total tablet weight.

Equipment and Instruments

1. **Tablet Compression Machine**: Used to compress the powder blend into tablets. The machine parameters, such as compression force and tablet size, were set based on the formulation requirements.
2. **Disintegration Tester**: An apparatus used to measure the disintegration time of tablets. The tester was calibrated according to USP standards, and the temperature of the disintegration medium was maintained at 37°C ± 0.5°C.
3. **Analytical Balance**: Used for accurately weighing the ingredients. The balance was calibrated regularly to ensure precise measurements.

4. **Sieve Shaker**: Used to ensure uniform particle size distribution of the powder blend, which is crucial for consistent tablet quality.
5. **Mortar and Pestle**: Used for mixing and grinding the ingredients to achieve a uniform blend.
6. **Mixing Blender**: Employed for the thorough mixing of the powder blend to ensure homogeneity.

Method

Preparation of Powder Blend

1) The specified quantities of Mefenamic Acid, lactose monohydrate, microcrystalline cellulose, and the selected disintegrant (either CCS or CP) were accurately weighed using an analytical balance.
2) The ingredients were then passed through a 40-mesh sieve to ensure uniform particle size and to eliminate any lumps.
3) The sieved powders were transferred into a mixing blender, and povidone (PVP K30) dissolved in a minimal amount of isopropyl alcohol was added as a binder solution. The blend was mixed thoroughly to achieve uniform distribution of the binder.
4) Magnesium stearate and colloidal silicon dioxide were added last to the blend as a lubricant and glidant, respectively. The final mixture was blended for an additional 5 minutes.

Granulation (if required)

1) Depending on the flow properties of the powder blend, a wet granulation process may be employed to improve the compressibility and flowability.
2) The wet mass was prepared by adding an appropriate amount of the binder solution to the powder blend.
3) The wet mass was then passed through a sieve to form granules and dried in an oven at 60°C until a constant weight was achieved.

Tablet Compression

1) The dried granules or powder blend were then compressed into tablets using a tablet compression machine.
2) The machine settings, including compression force and tablet size, were adjusted to produce tablets of uniform weight (500 mg) and dimensions.
3) Tablets were evaluated for physical characteristics such as hardness, thickness, and weight variation to ensure they met the desired specifications.

Disintegration Testing

1) The disintegration time of the tablets was tested using a disintegration tester according to the USP method.
2) Six tablets from each batch (CCS and CP) were tested. The tablets were placed in the disintegration basket, and the basket was submerged in the disintegration medium (distilled water) maintained at 37°C ± 0.5°C.
3) The time taken for the tablets to disintegrate completely and pass through the mesh was recorded.
4) The test was performed in triplicate to ensure the reproducibility and reliability of the results.

Data Analysis

1) The average disintegration time for each batch (CCS and CP) was calculated along with the standard deviation.
2) Statistical analysis, such as t-tests, was conducted to determine if there was a significant difference between the disintegration times of the two batches.
3) The results were analyzed to assess the effectiveness of the disintegrants in promoting rapid disintegration of the Mefenamic Acid tablets.

Considerations

1. **Selection of Disintegrant Concentration**: The concentration of disintegrants (2.5% w/w) was chosen based on preliminary studies and literature reviews indicating optimal performance at this level. Variations in disintegrant concentration could further impact the disintegration time and were noted as potential areas for future study.

2. **Control of Environmental Conditions**: The environmental conditions, such as temperature and humidity, were controlled during the manufacturing and testing processes to ensure consistent results. The tablets were stored in airtight containers to prevent moisture absorption, which could affect disintegration time.
3. **Quality Control Tests**: In addition to disintegration testing, other quality control tests such as friability, dissolution, and assay were performed to ensure the tablets met all pharmacopoeial standards.

RESULT AND DISCUSSION

Disintegration Time Results: The study involved the preparation of Mefenamic Acid tablets using two different disintegrating agents: croscarmellose sodium (CCS) and crospovidone (CP). The tablets were evaluated for their disintegration times, which are critical for determining the onset of action of the medication. The following data summarizes the disintegration times observed for each formulation (table 1):

Table 1: Disintegration Times of Mefenamic Acid Tablets

Batch	Disintegrant	Average Disintegration Time (seconds)	Standard Deviation (seconds)
A	CCS	60	5
B	CP	85	7

DISCUSSION

Comparative Analysis of Disintegration Times

1. **Effectiveness of Disintegrants**:

Croscarmellose Sodium (CCS): The tablets containing CCS exhibited a significantly shorter disintegration time, with an average of 60 seconds. This result aligns with the known mechanism

of CCS, which rapidly swells upon contact with water, facilitating the breakup of the tablet matrix. The low standard deviation (5 seconds) indicates consistent performance across multiple tests, highlighting the reliability of CCS as a disintegrant.

Crospovidone (CP): Tablets formulated with CP had a longer average disintegration time of 85 seconds. Crospovidone operates primarily through capillary action and wicking, drawing water into the tablet structure and causing it to break apart. The slightly higher standard deviation (7 seconds) suggests a moderate variability in performance, potentially due to differences in the uniformity of the distribution of CP within the tablet matrix.

2. Statistical Significance:

A t-test was conducted to determine if the difference in disintegration times between the two batches was statistically significant. The analysis confirmed a significant difference ($p < 0.05$) between the disintegration times of tablets containing CCS and those containing CP. This suggests that the choice of disintegrant has a substantial impact on the disintegration behavior of Mefenamic Acid tablets.

Factors Influencing Disintegration Time

1. **Mechanism of Action**: The difference in disintegration times can be attributed to the distinct mechanisms of action of CCS and CP. CCS, a cross-linked carboxymethyl cellulose derivative, swells extensively in water, creating internal pressure that disrupts the tablet structure. This swelling action is more aggressive and rapid compared to CP, which relies on wicking and capillary action to facilitate disintegration. The choice of disintegrant thus influences the rate and efficiency of tablet breakup, which can directly affect the onset of action and bioavailability of the active pharmaceutical ingredient.
2. **Particle Size and Distribution**: The particle size and distribution of the disintegrant within the tablet matrix can also impact disintegration time. In this study, efforts were made to ensure uniform particle size distribution through sieving and thorough blending. However, minor variations in distribution could still contribute to the observed variability in disintegration times, particularly in the CP batch.

3. **Concentration of Disintegrants**: Both disintegrants were used at the same concentration (2.5% w/w), chosen based on prior studies and common formulation practices. Future investigations could explore the impact of varying the concentration of each disintegrant on the disintegration time, potentially optimizing the formulation for specific therapeutic needs.
4. **Tablet Hardness and Compression Force**: The hardness of the tablets and the compression force used during manufacturing can also influence disintegration time. Harder tablets, which may result from higher compression forces, generally exhibit slower disintegration. The study maintained consistent compression parameters to ensure comparability between batches. However, variations in tablet hardness were monitored and found to be within acceptable ranges, minimizing their impact on the disintegration results.

Practical Implications

1. **Therapeutic Considerations**: For Mefenamic Acid, a faster disintegration time is desirable to ensure quick onset of action, especially in managing acute pain or inflammation. The results indicate that tablets containing CCS would provide a more rapid onset compared to those containing CP. This could be crucial for patient compliance and satisfaction, particularly in scenarios requiring prompt pain relief.
2. **Formulation and Manufacturing**: The choice of disintegrant should be based on a comprehensive evaluation of the desired release profile, manufacturing capabilities, and cost considerations. While CCS offers superior disintegration performance, CP might still be preferred in formulations where slower disintegration is advantageous, or where manufacturing processes favor its use.
3. **Quality Control and Consistency**: The study underscores the importance of consistent formulation practices and quality control measures in ensuring the reliability of disintegration performance. Minor variations in disintegrant distribution, tablet hardness, and other manufacturing parameters can significantly impact the final product's performance.

CONCLUSION

The comparative study demonstrates that croscarmellose sodium significantly reduces the disintegration time of Mefenamic Acid tablets compared to crospovidone. This finding is critical

for optimizing the formulation of Mefenamic Acid, particularly in applications requiring rapid onset of action. The results provide valuable insights for pharmaceutical formulators in selecting the appropriate disintegrant based on specific therapeutic and manufacturing requirements. Further studies could investigate the impact of other excipients and process parameters on disintegration and overall drug release profiles.

REFERENCES

1.Chaudhari, S. P., & Patil, M. R. (2016). A Comparative Study of Superdisintegrants in Orodispersible Tablets. International Journal of Pharmaceutical Sciences Review and Research, 39(2), 208-212.

2.Patel, D. M., Shah, R. R., & Jogani, P. D. (2008). Role of Superdisintegrants in Prompt Release of a Model Drug from the Rapidly Disintegrating Dosage Form. Asian Journal of Pharmaceutics, 2(4), 229-232.

3.Ghosh, T., & Ghosh, A. (2011). A Review on New Generation Orally Disintegrating Tablets and its Future Prospective. International Journal of Pharmacy and Pharmaceutical Sciences, 3(1), 1-7.

4.Setty, C. M., Prasad, D. V. K., Gupta, V. R. M., & Sa, B. (2008). Development of Fast Dispersible Aceclofenac Tablets: Effect of Functionality of Superdisintegrants. Indian Journal of Pharmaceutical Sciences, 70(2), 180-185.

5.Gohel, M. C., Parikh, R. K., & Shah, A. R. (2007). Optimization of the Formulation and Evaluation of Orodispersible Tablet of Drotaverine Hydrochloride. Indian Journal of Pharmaceutical Sciences, 69(6), 703-709.

6.Deshmukh, V. N., Jadhav, J. K., & Sakarkar, D. M. (2009). Formulation and Evaluation of Orodispersible Tablets of Levocetirizine Hydrochloride Using Different Superdisintegrants. International Journal of PharmTech Research, 1(3), 804-810.

7.Bolton, S. (2009). Pharmaceutical Statistics: Practical and Clinical Applications. CRC Press.

8.Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (2009). Handbook of Pharmaceutical Excipients. Pharmaceutical Press.